Borenius advised Danske Bank and DNB Carnegie, as joint global coordinators, on Bioretec’s fully guaranteed rights issue of EUR 9.2 million – the first in Finland to utilise the new EU exemption framework

We advised Danske Bank A/S, Finland Branch, and DNB Carnegie Investment Bank AB, Finland Branch, as joint global coordinators, on Bioretec Ltd’s fully guaranteed rights issue of EUR 9.2 million. This transaction is the first rights issue in Finland to take advantage of the new EU exemption framework introduced by the EU Listing Act in December 2024, with Bioretec publishing an 11-page exemption document.

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The Company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. Bioretec’s shares are listed on the Nasdaq First North Growth Market Finland.